Jefferies is expected to report Q3 earnings of $1.04 per share, down 1% year-over-year, with revenues forecast at $2.21 billion, up 8.1%. EPS estimates have been revised 8.1% higher over the last 30 days. Key metrics show mixed performance: Asset Management revenues declining 35.6%, while Investment Banking and Capital...
Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with...
SpaceX's IPO experienced significant volatility after investors grew concerned about the company's massive AI spending ($28.5B capex with 86% going to AI infrastructure) despite modest revenue ($12.5B). Historical data shows large IPOs average only 3.5% returns over 12 months despite strong first-week gains. The...
TJX Companies' stock dropped nearly 15% in August despite solid Q2 2027 earnings with 5% revenue growth and 22% net income increase. The decline was driven by the company's full-year adjusted earnings guidance of $5.15-$5.20 per share falling short of analyst expectations of $5.22, combined with downgrades from...
Salesforce stock surged 22% this week after beating Q2 2027 earnings expectations with $11.35B in revenue versus $11.32B expected, and posting $4.29 diluted EPS versus $3.27 anticipated. The company raised its fiscal 2027 revenue guidance to $46.1-$46.4B and EPS guidance to $10.21-$10.25, prompting analysts to raise...
Kirby McInerney LLP is investigating Jefferies Financial Group for potential securities law violations related to alleged misleading disclosures about the company's exposure to First Brands Group, a bankrupt auto-parts supplier, through its asset-management unit Point Bonita Capital. The SEC is reportedly investigating...
Historical data suggests investors should wait until mid-2027 or later before buying SpaceX stock, despite the company's recent IPO and operational achievements. Large IPOs typically underperform their market index by 4% over three years, and SpaceX's high P/S ratio of 76 (versus tech sector average of 9) indicates...
Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint...
SpaceX stock, which opened at $150 over a month ago, is now trading below that level. Based on 26 years of historical IPO data, large IPOs typically gain only 3.5-4% in their first year, suggesting SpaceX shares could reach around $156 within 11 months. The company faces headwinds including unprofitability, massive...
Law firm Bragar Eagel & Squire is investigating Jefferies Financial Group for potential securities violations related to its Point Bonita Capital fund's $715 million exposure to bankrupt auto supplier First Brands. The investigation follows SEC inquiry into whether Jefferies adequately disclosed risks to investors....
The Portnoy Law Firm has initiated a securities fraud investigation into Jefferies Financial Group following significant losses tied to auto supplier First Brands' bankruptcy. Jefferies' Point Bonita Capital fund faced approximately $715 million in exposure to First Brands. The company took a $30 million loss and...
Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock...
Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following...
Vertex (VERX) stock rose following TD Cowen's initiation of coverage with a buy rating and $14 price target, implying 23.1% upside. The analyst believes the company can maintain double-digit revenue growth through fiscal 2028. Despite a 41% year-to-date decline, Vertex trades at a discount to historical valuations with...
Jefferies Financial reported mixed Q2 earnings with net earnings and revenue missing estimates, but achieved record investment banking revenue of $1.2 billion (up 58% YoY). While asset management revenue declined 46% due to market weakness and Point Bonita losses, the strong investment banking results suggest upcoming...
SpaceX stock surged 20% on its IPO day and has continued climbing, but historical data suggests investors should wait before buying. Large IPOs that gain 26.5% in their first week typically only gain 3.5% over the following year. With SpaceX trading at a premium valuation (P/S of 130 vs. 10 for average tech stocks),...
Law firm Robbins Geller is investigating Jefferies Financial Group for potential securities law violations related to false or misleading statements regarding First Brands' bankruptcy. Jefferies' Point Bonita Capital division is owed approximately $715 million from First Brands, and the company allegedly failed to...
Kratos Defense & Security Solutions stock dropped despite beating earnings, with five out of six analysts cutting price targets. The company reported 23% sales growth and doubled GAAP income, but continues to burn cash with negative free cash flow of $47.3 million. At a valuation of 340 times earnings, analysts remain...
Suja Life, Inc. announced the pricing of its IPO at $21.00 per share for 8,888,889 shares of Class A common stock. The company expects to raise approximately $173.6 million in net proceeds, which will be used to acquire LP units in its parent entity and repay $141.3 million in outstanding debt. Trading is expected to...
Despite Palantir delivering strong Q1 2026 earnings with 85% revenue growth and beat-and-raise guidance across all metrics, the stock declined significantly. Two main issues are weighing on the stock: a miss on U.S. commercial revenue guidance ($595M vs. $605M expected) and ultra-high valuation expectations that make...
Headlines via Polygon.io. Links open the original publisher.